### **EPIDEMIC ESTIMATES**

| New HIV infections                  |                  |                 |                  |
|-------------------------------------|------------------|-----------------|------------------|
| New HIV infections (all ages)       | 1000             | 720             | 570              |
|                                     | [900–1100]       | [650–790]       | [510–630]        |
| New HIV infections (0-14)           | <200             | <100            | <100             |
|                                     | [<200– <200]     | [<100– <200]    | [<100– <100]     |
| New HIV infections (women, 15+)     | <500             | <500            | <200             |
|                                     | [<500– <500]     | [<500– <500]    | [<200– <500]     |
| New HIV infections (men, 15+)       | <500             | <500            | <500             |
|                                     | [<500–520]       | [<500– <500]    | [<500– <500]     |
| HIV incidence per 1000 population   | 0.16 [0.15–0.18] | 0.11 [0.1–0.12] | 0.08 [0.07–0.09] |
| AIDS-related deaths                 |                  |                 |                  |
| AIDS-related deaths (all ages)      | <500             | <500            | <500             |
|                                     | [<500– <500]     | [<500– <500]    | [<500– <500]     |
| AIDS-related deaths (0-14)          | <100             | <100            | <100             |
|                                     | [<100– <100]     | [<100– <100]    | [<100– <100]     |
| AIDS-related deaths (women, 15+)    | <200             | <200            | <200             |
|                                     | [<100– <200]     | [<100– <200]    | [<100– <200]     |
| AIDS-related deaths (men, 15+)      | <200             | <200            | <200             |
|                                     | [<200– <500]     | [<200– <500]    | [<200– <200]     |
| People living with HIV              |                  |                 |                  |
| People living with HIV (all ages)   | 9900             | 11 000          | 12 000           |
|                                     | [8800–11 000]    | [10 000–13 000] | [11 000–14 000]  |
| People living with HIV (0–14)       | 550              | 700             | 700              |
|                                     | [<500–640]       | [620–810]       | [620–820]        |
| People living with HIV (women, 15+) | 4200             | 4800            | 5000             |
|                                     | [3700–4700]      | [4300–5500]     | [4500–5700]      |
| People living with HIV (men, 15+)   | 5200             | 5900            | 6300             |
|                                     | [4600–6000]      | [5200–6900]     | [5500–7300]      |
| HIV prevalence (15–49)              | 0.3 [0.2–0.3]    | 0.3 [0.2–0.3]   | 0.3 [0.2–0.3]    |

## LAWS AND POLICIES

Laws criminalizing the transmission of, nondisclosure of or exposure to HIV transmission

Criminalization of sex work among consenting adults

| Criminalization of same-sex sexual acts  | Laws penalizing same-sex sexual acts have been decriminalized or never existed |
|--|--|
| Drug use or possession for personal use is an offence                                |  |
| Criminalization of transgender people  |  |
| Laws or policies restricting the entry, stay and residence of people living with HIV | No   |
| Parental consent for adolescents to access HIV testing                               | · · · ·  |
| Spousal consent for married women to access sexual and reproductive health services  |  |
| Mandatory HIV testing for marriage, work or  |  |

Mandatory HIV testing for marriage, work or residence permits or for certain groups

#### **STIGMA AND DISCRIMINATION**

| Percentage of women and men aged 15–49<br>years who report discriminatory attitudes                                 | 2017 |
|---|------|
| towards people living with HIV  | 48.1 |
| Percentage of people living with HIV denied<br>health services because of their HIV status in<br>the last 12 months |      |
|   |      |

Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent


# VIOLENCE

Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

## **EXPENDITURES**

| Financing sources           |  |           |           |             |           |             |
|-----------------------------|--|-----------|-----------|-------------|-----------|-------------|
|                             |  |           |           |             |           |             |
| Last available report: 2017 |  | \$569 221 | \$459 782 | \$3 246 284 | \$358 204 | \$4 633 491 |


### **EPIDEMIC TRANSITION METRICS**



## **KEY POPULATIONS**

| Estimated size of population                                  | 14 000    | 17 000    |          | <br> |
|---|-----------|-----------|----------|------|
| HIV prevalence  | 1.0%      | 2.8%      |          | <br> |
| Know their HIV status   | 95.4%     | 10.2%     |          |      |
| Antiretroviral therapy coverage                               |           |           |          | <br> |
| Condom use  | 91.8%     | 25.7%     |          |      |
| Coverage of HIV prevention programmes                         | 50.7%     | 7.8%      |          |      |
| Avoidance of health care because of stigma and discrimination | 2.3%      | 75.0%     |          |      |
| Expenditures (2017)   | \$329 955 | \$675 288 | \$20 413 |      |

# HIV TESTING AND TREATMENT CASCADE



| All ages        | 05%[75-275%] | 6500                 | 47 /0 [41-54 /0] |
|-----------------|--------------|----------------------|------------------|
| Children (0-14) | % [–%]       | 40% [35–46%]<br>280  | 35% [30–40%]     |
| Women (15+)     | % [–%]       | 57% [51–64%]<br>2800 | 52% [47–59%]     |
| Men (15+)       | % [–%]       | 54% [47–62%]<br>3400 | 44% [39–51%]     |

## ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

| Percentage of pregnant women living with HIV | 8%        | 35%          |
|--|-----------|--------------|
| accessing antiretroviral medicines           | [6–9%]    | [31–41%]     |
| Early infant diagnosis                       | <1%       | 12.7%        |
| Larry mant diagnosis                         | [<1–1.1%] | [10.9–14.7%] |

# **HIV COMORBIDITIES**

| Estimated number of incident tuberculosis cases among people living with HIV (2017) | 680<br>[430–980] |
|---|------------------|
| People living with HIV who started TB preventive therapy (2017)                     |                  |
| Cervical cancer screening of women living with HIV                                  |                  |
| People coinfected with HIV and hepatitis B virus receiving combined treatment       |                  |
| People coinfected with HIV and hepatitis C virus starting hepatitis C treatment     |                  |

# **HIV PREVENTION**

| Adults aged 15+ years with unsuppressed viral load   | 0.1%              |
|--|-------------------|
| Knowledge of HIV prevention among young people aged 15–24 years                                    |                   |
| — Women  |                   |
| — Men  |                   |
| Condom use at last sex with a non-marital, non-cohabiting partner                                  |                   |
| — Women  |                   |
| — Men  |                   |
| Women aged 15–49 years who have their<br>demand for family planning satisfied by<br>modern methods |                   |
| Men aged 15–49 years who are circumcised   | Not<br>applicable |
| Voluntary medical male circumcisions performed according to national standards                     | Not<br>applicable |
| People who received PrEP at least once<br>during the reporting period                              |                   |
| Harm reduction   |                   |
| <ul> <li>Use of sterile injecting equipment at<br/>last injection</li> </ul>                       |                   |
| <ul> <li>Needles and syringes distributed per<br/>person who injects (2017)</li> </ul>             | 3                 |
| <ul> <li>Coverage of opioid substitution<br/>therapy</li> </ul>                                    |                   |
| — Naloxone available (2019)  |                   |
| — Safe injection rooms available (2019)  |                   |